| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7955619 | PROTEGA PHARMS | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(4 years from now) | |
| US10314788 | PROTEGA PHARMS | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(4 years from now) | |
Roxybond is owned by Protega Pharms.
Roxybond contains Oxycodone Hydrochloride.
Roxybond has a total of 2 drug patents out of which 0 drug patents have expired.
Roxybond was authorised for market use on 20 April, 2017.
Roxybond is available in tablet;oral dosage forms.
The generics of Roxybond are possible to be released after 12 August, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 20, 2020 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
ROXYBOND family patents
